NASDAQ:PTCT - PTC Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.90
  • Forecasted Upside: 32.96 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$48.81
▲ +1.5 (3.17%)
1 month | 3 months | 12 months
Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$64.90
▲ +32.96% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $64.90, with a high forecast of $86.00 and a low forecast of $47.00. The average price target represents a 32.96% upside from the last price of $48.81.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in PTC Therapeutics. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/21/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/18/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/17/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/15/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2021Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$47.00Medium
i
2/26/2021Cantor FitzgeraldLower Price TargetOverweight$81.00 ➝ $75.00High
i
2/12/2021Bank of AmericaDowngradeBuy ➝ NeutralLow
i
1/5/2021Smith Barney CitigroupUpgradeNeutral ➝ BuyN/A
i
1/5/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ Buy$67.00 ➝ $85.00N/A
i
12/16/2020Raymond JamesBoost Price TargetOutperform$63.00 ➝ $70.00Medium
i
11/30/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$45.00High
i
10/30/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralMedium
i
10/30/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ NeutralMedium
i
10/30/2020Cantor FitzgeraldLower Price TargetOverweight$75.00 ➝ $67.00High
i
10/28/2020UBS GroupInitiated CoverageNeutral$55.00Medium
i
10/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$71.00High
i
9/23/2020Raymond JamesReiterated RatingBuyMedium
i
8/24/2020Raymond JamesInitiated CoverageOutperform$63.00High
i
8/11/2020Cantor FitzgeraldLower Price TargetOverweight$85.00 ➝ $75.00Low
i
Rating by Alethia Young at Cantor Fitzgerald
8/10/2020Bank of AmericaLower Price TargetBuy$60.00 ➝ $58.00Medium
i
8/10/2020Credit Suisse GroupLower Price TargetNeutral$53.00 ➝ $52.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
7/20/2020CowenReiterated RatingHold$50.00High
i
Rating by Joseph Thome at Cowen Inc
7/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$53.00High
i
7/20/2020SunTrust BanksBoost Price TargetBuy$75.00 ➝ $86.00High
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/1/2020SunTrust BanksLower Price TargetBuy$78.00 ➝ $75.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
4/28/2020William BlairReiterated RatingBuyLow
i
4/9/2020CitigroupUpgradeNeutral ➝ Buy$71.00 ➝ $67.00High
i
4/8/2020Cantor FitzgeraldLower Price TargetOverweight$86.00 ➝ $85.00Medium
i
Rating by Alethia Young at Cantor Fitzgerald
4/8/2020Royal Bank of CanadaReiterated RatingHold$45.00High
i
3/4/2020BarclaysReiterated RatingHold$51.00High
i
3/3/2020Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$81.00 ➝ $86.00High
i
Rating by Alethia Young at Cantor Fitzgerald
3/2/2020CowenReiterated RatingHoldHigh
i
2/20/2020CitigroupDowngradeBuy ➝ Neutral$55.00 ➝ $71.00High
i
Rating by Joel Beatty at Citigroup Inc.
2/20/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$63.00 ➝ $60.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
2/6/2020SunTrust BanksReiterated RatingBuy$78.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
2/6/2020CowenReiterated RatingHoldHigh
i
1/23/2020Cantor FitzgeraldBoost Price TargetOverweight$60.00 ➝ $81.00Low
i
Rating by Alethia Young at Cantor Fitzgerald
1/15/2020Cantor FitzgeraldReiterated RatingBuy$60.00Medium
i
Rating by Alethia Young at Cantor Fitzgerald
12/5/2019Royal Bank of CanadaReiterated RatingOutperform$58.00Medium
i
Rating by Brian Abrahams at Royal Bank of Canada
11/26/2019William BlairReiterated RatingBuyLow
i
11/12/2019SunTrust BanksInitiated CoverageBuy$78.00Low
i
10/31/2019Credit Suisse GroupReiterated RatingBuy$54.00Low
i
10/30/2019CowenReiterated RatingHoldHigh
i
9/26/2019CitigroupSet Price TargetBuy$62.00High
i
Rating by Joel Beatty at Citigroup Inc.
9/24/2019Royal Bank of CanadaReiterated RatingBuyHigh
i
Rating by Brian Abrahams at Royal Bank of Canada
8/12/2019BarclaysReiterated RatingHold$43.00Low
i
5/13/2019Bank of AmericaUpgradeNeutral ➝ Buy$43.00 ➝ $49.00Low
i
5/8/2019CowenReiterated RatingHoldHigh
i
5/3/2019CitigroupSet Price TargetBuy$59.00Low
i
Rating by Joel Beatty at Citigroup Inc.
5/2/2019CowenReiterated RatingHoldHigh
i
4/11/2019Sanford C. BernsteinInitiated CoverageOutperform$48.00Low
i
2/28/2019Cantor FitzgeraldReiterated RatingBuy$61.00High
i
1/29/2019Credit Suisse GroupSet Price TargetBuy$51.00High
i
Rating by Martin Auster at Credit Suisse Group AG
1/7/2019William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
1/7/2019Credit Suisse GroupReiterated RatingBuy$55.00High
i
Rating by Martin Auster at Credit Suisse Group AG
1/7/2019Cantor FitzgeraldReiterated RatingBuy$61.00High
i
11/12/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$66.00 ➝ $61.00High
i
11/6/2018Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$51.00 ➝ $46.00High
i
11/6/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$43.00 ➝ $40.00High
i
11/6/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
11/5/2018Credit Suisse GroupSet Price TargetBuy$55.00High
i
Rating by Martin Auster at Credit Suisse Group AG
10/3/2018Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
i
10/3/2018Credit Suisse GroupSet Price TargetBuy$55.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
10/3/2018William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$66.00Medium
i
9/28/2018JPMorgan Chase & Co.Boost Price TargetPositive ➝ Neutral$51.00Low
i
9/5/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$49.00 ➝ $53.00Low
i
8/8/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $43.00High
i
7/31/2018Bank of AmericaBoost Price TargetUnderperform ➝ Underperform$27.00 ➝ $31.00High
i
7/24/2018CitigroupReiterated RatingBuy ➝ Buy$35.00 ➝ $50.00Low
i
Rating by Joel Beatty at Citigroup Inc.
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$49.00High
i
6/20/2018BarclaysUpgradeUnderweight ➝ Equal WeightHigh
i
6/18/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Raju Prasad at William Blair
6/18/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$11.00High
i
5/10/2018William BlairReiterated RatingHoldHigh
i
Rating by Raju Prasad at William Blair
4/3/2018BarclaysDowngradeEqual Weight ➝ Underweight$24.00 ➝ $26.00High
i
3/7/2018BarclaysReiterated RatingEqual Weight ➝ Equal Weight$18.00 ➝ $24.00High
i
3/7/2018William BlairReiterated RatingHoldHigh
i
2/21/2018CitigroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.00High
i
1/30/2018Credit Suisse GroupReiterated RatingBuy$28.00Medium
i
1/29/2018Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector PerformHigh
i
Rating by Matthew Eckler at Royal Bank of Canada
1/23/2018BarclaysReiterated RatingHoldLow
i
11/24/2017JPMorgan Chase & Co.Boost Price TargetUnderweight ➝ Neutral$15.00N/A
i
11/16/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$15.00N/A
i
10/26/2017Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
10/25/2017CowenReiterated RatingHoldN/A
i
10/25/2017Royal Bank of CanadaSet Price TargetHold$15.00N/A
i
Rating by Matthew Eckler at Royal Bank of Canada
10/9/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$23.00 ➝ $15.00N/A
i
9/29/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector PerformHigh
i
Rating by Matthew Eckler at Royal Bank of Canada
9/29/2017BarclaysLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $15.00High
i
9/27/2017CitigroupReiterated RatingBuy$28.00Low
i
Rating by Joel Beatty at Citigroup Inc.
9/26/2017Credit Suisse GroupReiterated RatingOutperform$25.00High
i
9/26/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
9/8/2017BarclaysReiterated RatingHold$22.00Low
i
8/23/2017William BlairInitiated CoverageMkt Perform ➝ Market Perform$17.00Low
i
Rating by R. Prasad at William Blair
7/20/2017CitigroupReiterated RatingBuy$28.00 ➝ $17.00High
i
Rating by Joel Beatty at Citigroup Inc.
6/30/2017JPMorgan Chase & Co.Reiterated RatingNeutral$15.00 ➝ $21.00Low
i
6/7/2017CitigroupSet Price TargetBuy$15.00 ➝ $18.00High
i
5/8/2017Royal Bank of CanadaSet Price TargetHold$12.00High
i
Rating by Matthew Eckler at Royal Bank of Canada
3/22/2017BarclaysReiterated RatingEqual Weight$13.00Medium
i
3/16/2017CowenReiterated RatingHoldHigh
i
3/16/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$13.00 ➝ $10.00High
i
3/6/2017Royal Bank of CanadaReiterated RatingSector Perform$13.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
3/6/2017Credit Suisse GroupReiterated RatingOutperform ➝ Positive$25.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
3/3/2017BarclaysDowngradeOverweight ➝ Equal Weight$20.00 ➝ $13.00N/A
i
2/16/2017Credit Suisse GroupReiterated RatingPositiveN/A
i
Rating by Alethia Young at Credit Suisse Group AG
1/10/2017Jefferies Financial GroupReiterated RatingHold$12.00N/A
i
Rating by gena wang at Jefferies Financial Group Inc.
1/2/2017Royal Bank of CanadaSet Price TargetHold$13.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
11/14/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$15.00 ➝ $25.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
11/11/2016WedbushReiterated RatingNeutral$12.00 ➝ $7.00N/A
i
11/11/2016Royal Bank of CanadaBoost Price TargetHold$13.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
11/11/2016Royal Bank of CanadaLower Price TargetSector Perform$13.00N/A
i
11/11/2016CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $15.00N/A
i
11/4/2016CowenReiterated RatingMarket PerformN/A
i
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$15.00N/A
i
11/3/2016WedbushReiterated RatingNeutral$7.00 ➝ $10.00N/A
i
10/11/2016WedbushReiterated RatingNeutral$10.00N/A
i
10/11/2016Credit Suisse GroupBoost Price TargetNeutral$15.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
10/3/2016Bank of AmericaReiterated RatingHold$15.00N/A
i
9/22/2016Jefferies Financial GroupReiterated RatingHold$7.00N/A
i
Rating by gena wang at Jefferies Financial Group Inc.
8/8/2016CitigroupBoost Price TargetNeutral$8.00 ➝ $9.00N/A
i
8/7/2016CowenReiterated RatingHoldN/A
i
Rating by Ritu Baral at Cowen Inc
8/5/2016JPMorgan Chase & Co.Lower Price TargetNeutral$18.00 ➝ $17.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
8/5/2016Credit Suisse GroupSet Price TargetHold$6.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
8/5/2016WedbushReiterated RatingNeutral$10.00N/A
i
Rating by Heather Behanna at Wedbush
8/2/2016CitigroupReiterated RatingBuy$48.00N/A
i
7/26/2016WedbushLower Price TargetNeutral$12.00 ➝ $10.00N/A
i
Rating by Heather Behanna at Wedbush
7/26/2016Credit Suisse GroupDowngradeOutperform ➝ NeutralN/A
i
Rating by Alethia Young at Credit Suisse Group AG
7/20/2016WedbushReiterated RatingNeutral$12.00N/A
i
Rating by Heather Behanna at Wedbush
5/6/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Alethia Young at Credit Suisse Group AG
5/6/2016Jefferies Financial GroupReiterated RatingHold$8.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
4/18/2016Royal Bank of CanadaReiterated RatingSector Perform$9.00N/A
i
4/17/2016OppenheimerReiterated RatingBuy$39.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Ritu Baral at Cowen Inc
(Data available from 4/14/2016 forward)
PTC Therapeutics logo
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Read More

Today's Range

Now: $48.81
$47.30
$48.85

50 Day Range

MA: $53.84
$46.80
$60.14

52 Week Range

Now: $48.81
$43.65
$70.82

Volume

1,923 shs

Average Volume

547,068 shs

Market Capitalization

$3.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Cantor Fitzgerald, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Raymond James, Royal Bank of Canada, Smith Barney Citigroup, SunTrust Banks, Inc., UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PTCT.

What is the current price target for PTC Therapeutics?

10 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $64.90, suggesting a possible upside of 37.2%. SunTrust Banks, Inc. has the highest price target set, predicting PTCT will reach $86.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $47.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.

What is the current consensus analyst rating for PTC Therapeutics?

PTC Therapeutics currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTCT will outperform the market and that investors should add to their positions of PTC Therapeutics.
View the latest ratings for PTCT.

What other companies compete with PTC Therapeutics?

How do I contact PTC Therapeutics' investor relations team?

PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is 908-222-7000 and its investor relations email address is [email protected] The official website for PTC Therapeutics is www.ptcbio.com.